AstraZeneca PLC and Sanofi’s proposed RSV prevention treatment nirsevimab did not appear to present any major problems for the US Food and Drug Administration with an advisory committee meeting approaching, but the agency does have questions about it should be used if pediatric RSV vaccines were to reach the market.
Nirsevimab, also known as Beyfortus, is proposed for prevention of RSV lower respiratory tract disease in neonates and infants born...